tazobactam
Commercial- Indications
- Bacterial infections
Company intelligence / Profile preview
Jiangxi Fushine Pharmaceutical specializes in the R&D, manufacturing, and sales of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It is a leading Chinese manufacturer of β-lactamase inhibitors and carbapenem intermediates. The company also offers contract research, development, and manufacturing services. Its products are exported globally. Clinical activities include at least one Phase III trial for a combination omeprazole capsule targeting duodenal ulcers and bioequivalence studies on metformin sustained-release tablets.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jiangxi Fushine Pharmaceutical.